96 results about "Food intake" patented technology

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

A system includes a processor that collects data representing activity levels, sleep patterns, and food intake from an information collection device attached to a dog, transmits the collected data to an analysis server, wherein the analysis server inputs the collected data into a generative artificial intelligence model and analyzes the data, transmits analysis results to a terminal and notifies a user, receives user input regarding questions or symptoms of the dog and generates advice using the generative artificial intelligence model, transmits the generated advice to the terminal for display to the user, and provides online consultation reservation with a veterinarian.

The images related to this design are used, for example, to monitor, display, or track measurement data such as blood glucose levels, as well as exercise, insulin administration, and food intake. These images can be operated by tapping, pressing, swiping, or scrolling the display screen, or via other devices associated with the display device.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing visceral fat in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards5 to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The objective is to provide a diversity assessment device, a diversity assessment method, and a diversity assessment program that can assess food diversity while considering nutrient diversity by evaluating the diversity of ingested foods based on clusters that classify foods. [Solution] Based on food component data, a food classification is set by classifying the target specified foods according to nutrients using a clustering method, data on the intake status of specified foods included in a meal classified according to the food classification is obtained, and a dietary diversity score is calculated for the specified food intake status data.

An object of the system according to the embodiment is to check a health condition by comprehensively analyzing daily health data and video data.SOLUTION: A system includes a data storage part, a health condition check part, a video recording part, and a motion analysis part. The data storage unit stores data of a meal amount, an exercise amount, and excretion. The health condition check unit checks a health condition using the data accumulated by the data accumulation unit. The video recording unit records daily video data. The motion analysis unit analyzes the video data recorded by the video recording unit to detect a change in motion or an injury.SELECTED DRAWING: Figure 1

The invention relates to the technical field of milk intake monitoring, and discloses an automatic monitoring and recording device for milk intake. Which comprises a feeding bottle body and is characterized in that a bottle cap is installed at the top of the feeding bottle body, a measuring assembly is arranged on the outer side of the feeding bottle body and comprises a first rubber pad and a second rubber pad which are fixed to the inner wall of the bottle cap, and a soft tape is installed between the first rubber pad and the second rubber pad; by arranging the monitoring assembly, the milk intake can be conveniently and automatically monitored, the feeding time or the feeding amount of each time can be recorded in real time, errors of a traditional measuring method are avoided, accurate milk intake information is provided for parents and medical staff, the diet law of a baby can be analyzed, and the feeding efficiency of the baby is improved. By arranging the measuring assembly, the soft measuring tape can be conveniently stored in the bottle cap, the soft measuring tape can be properly stored and kept clean and tidy, the bottle cap can be conveniently used next time, meanwhile, carrying and storing are convenient, and convenience is improved.

A Lacticaseibacillus rhamnosus MBP01 and a combination thereof for preventing and treating irritable bowel syndrome are provided, which relates to the technical field of microorganism. A deposit number of the Lacticaseibacillus rhamnosus MBP01 is GDMCC NO: 64725. The MBP01 can improve a weight loss trend of IBS model mice, increase food intake and feces water content, alleviate colon tissue damage, downregulate expression levels of IL-1β, TNF-α, PAR-2, and serum CORT and increase an expression level of IL-10. MBP01 with a high concentration can improve an expression level of OCC. Therefore, MBP01 has a certain positive regulatory effect on the intestinal function of IBS model mice and can effectively prevent and treat irritable bowel syndrome.

The invention provides a dietary fiber composition capable of reducing calorie intake and slowing down digestion speed and a preparation method thereof, and belongs to the technical field of weight control. The feed additive is prepared from the following raw materials in parts by weight: 18-20 parts of sodium carboxymethyl cellulose, 1-2 parts of lecithin, 15-18 parts of modified konjac glucomannan, 4-8 parts of L-carnitine, 4-8 parts of a white kidney bean extract, 1-2 parts of chlorogenic acid and 3-5 parts of probiotics. The dietary fiber composition capable of reducing calorie intake and slowing down digestion speed, prepared by the invention, regulates fat metabolism in a targeted manner through multiple metabolism, reduces calorie intake, slows down digestion speed, improves glucose metabolism in a body, improves calorie consumption of the body, reduces fat hoarding, improves satiety, reduces food intake, prolongs the duration time of satiety, and has the efficacy of reducing calorie intake and slowing down digestion speed. Therefore, a good body weight control effect is achieved, and wide application prospects are achieved.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The invention relates to an efficient energy supply type laboratory mouse feed which comprises the following components in percentage by weight: 20-40% of corn, 10-30% of wheat, 1-5% of wheat middling, 4-10% of soybean meal, 2-8% of fish meal, 2-6% of chicken meal, 1-10% of soybean hull, 1-5% of soybean oil, 1-5% of lard, 0.5-2% of stone powder, 0.5-1.5% of calcium hydrophosphate, 2-5% of premix, 1-5% of MCT microcapsule powder and 0.5-2% of glutamine. The stability of MCT is improved through a microencapsulation method, the activity of glutamine is reserved through an embedding method, the synergistic effect of MCT microcapsule powder and glutamine is utilized, meanwhile, lard oil and fat raw materials are added, high-temperature steam is used for curing materials in the production process, the fragrance of the feed is further improved, the palatability of the feed is jointly improved, the food intake of laboratory mice is not affected, and the production cost is reduced. The utilization efficiency of the feed is improved; the experimental mouse feed can reduce body fat and improve blood lipid level, can effectively prolong exhaustion time of mice, and is suitable for cultivation and maintenance of special experimental animals such as intestinal injury models and immunodeficiency models.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

The present invention provides novel compounds that are peptide hormone analogs and are useful for treating disorders such as diabetes and obesity.The compounds of the general sequence listed herein have tailored profiles of potency at the GIP receptor.Regarding in vivo properties, administration of exemplary peptides of the present invention has been shown to result in improved weight loss in animal models.Preferred compounds achieve this without significantly reducing food intake.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The utility model relates to a healthy diet calculating device for diabetes mellitus, which comprises a hollow box body with an opening at the top end, a partition plate is arranged in the box body, and the interior of the box body is divided into a left chamber and a right chamber by the partition plate; the partition plate is slidably connected with the box body in the length direction of the box body. The problems that in the prior art, when the required intake amount of food is not enough to fill a measuring cup, the volume of food added into the measuring cup needs to be manually adjusted and controlled, and whether the adding amount is enough or not is judged by visually observing marks such as scale marks on the side wall of the measuring cup, and the operation is troublesome are solved.

The use of a postbiotic of Bifidobacterium brevis 207-1 (GDMCC No. 60962) or a composition containing the postbiotic in the preparation of a medicine or a food product. The medicine or food product is used for preventing and / or ameliorating diseases and / or symptoms related to fat gain in a subject. The diseases and / or symptoms are selected from weight gain, obesity, fatty liver, fat accumulation (e.g., visceral fat accumulation and subcutaneous fat accumulation), abnormal lipid metabolism, or any combination thereof. The medicine or food product can promote the fat breakdown and / or inhibit the fat absorption, maintain or reduce the body weight and / or BMI of the subject, increase the satiety of the subject, and reduce the food intake of the subject.

The system according to this embodiment aims to comprehensively manage the health status of pets and detect abnormalities at an early stage. [Solution] The system according to the embodiment comprises a collection unit, an analysis unit, a notification unit, and a recording unit. The collection unit collects data on the pet's food intake, exercise level, and excretion. The analysis unit analyzes the data collected by the collection unit and checks the pet's health status. The notification unit, based on the data analyzed by the analysis unit, alerts the pet to take necessary action if there are concerns about its health status. The recording unit records daily video data and detects changes in movement and injuries.

The invention relates to the technical field of health management, in particular to a blood glucose monitoring computer intelligent analysis system and method based on AI drive, and the system comprises a fluctuation trend recognition module, an aggregation window screening module, a feeding response judgment module, a behavior deviation analysis module and an intervention level judgment module. According to the method, through dynamic trend decomposition and interval fluctuation feature fusion of blood glucose monitoring data, trend clustering and high-risk interval active identification of blood glucose changes in a continuous time period are achieved, multi-source behavior information collaboratively analyzes blood glucose responses of events such as feeding, exercise and medication, tracing judgment is carried out on abnormal signals through multi-parameter interaction verification, and the accuracy of blood glucose monitoring is improved. The behavior migration factors and risk influences are quantified and layered in real time, the linkage judgment ability of blood glucose changes and various behavior situations is enhanced, the intervention priority of behavior events is dynamically optimized, and individualized and graded response and active adjustment in a chronic disease health management scene are promoted.

The present application discloses a two-arm branched fatty acid side chain, a receptor agonist modified therewith, and a use thereof. By adjusting the number and structure of side chain arms of the fatty acid chain, optimizing the type of a core molecule, and using the fatty acid chain to modify a receptor agonist, the present application significantly improves the physical and chemical stability of the receptor agonist and the therapeutic effect of the receptor agonist on reducing blood glucose and body weight. The fatty acid chain and the receptor agonist modified therewith disclosed in the present application can reduce blood glucose levels and improve sugar tolerance and has the effects of controlling appetite, food intake, and caloric intake, increasing energy consumption, preventing weight gain, promoting weight loss, and reducing excess body weight. In addition, the fatty acid chain and the receptor agonist modified therewith disclosed in the present application have relatively long half-life and can effectively prolong in vivo drug actions.

The invention relates to the technical field of infant diet management, and discloses an infant nutrition intake analysis and diet intelligent management method. The method comprises the following steps: interactively obtaining physiological characteristic parameters and diet history parameters of an infant individual; determining nutritional requirement type selection, and obtaining a target diet plan; interactively acquiring target structure features of the target diet plan, initializing diet management conditions in combination with nutritional demand selection, and outputting initial management control constraints including a nutrition intake threshold and a maximum allowable deviation rate; taking the initial management control constraint as an optimization condition, optimizing the ingestion preparation speed according to the food ingestion record information and the preset time constraint, and positioning the ingestion control speed; analyzing a nutrition deviation trend of the target diet plan according to the intake control speed, and optimizing diet adjustment control parameters based on an analysis result; and when food intake is managed according to the intake control speed during diet execution, intermittently and automatically adjusting the target diet plan by using the diet adjustment control parameters.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease DPP-4 activity or levels, visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing or decreasing DPP-4 activity or levels in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The present disclosure relates generally to a method for selecting a predetermined product set for a patient at risk of developing pressure ulcers, comprising: a) determining a plurality of risk parameters associated with the patient, wherein the plurality of risk parameters is selected from the group consisting of sensory perception, moisture exposure, degree of physical activity, mobility, friction and / or shear, skin condition, medication, trauma, fluid and / or food intake pattern, length of hospital stay, perfusion and / or medical condition, b) assessing a risk score associated with the patient based on the risk parameters, c) selecting a predetermined product set based on the risk score, wherein the predetermined product set is selected from at least a standard risk product set and a high risk product set, wherein the standard risk product set comprises a first preventive dressing, a second preventive dressing and a third preventive dressing; the first preventive dressing is a sacral dressing (200); the second and third preventive dressing are heel dressings (300), and the high risk product set comprises the first, second and third preventive dressing, and at least one additional preventive dressing or preventive product. The present disclosure also relates to a product array comprising the standard risk product set and the high risk product set.

According to an embodiment of the present disclosure, a wearable electronic device may comprise: a plurality of sensors for acquiring user activity data; a communication module including at least one communication circuit; a memory for storing instructions; and at least one processor operatively connected to the communication module and the memory. According to an embodiment of the present disclosure, the instructions may cause, when executed by the at least one processor, the wearable electronic device to: acquire user activity data from at least one of the plurality of sensors; analyze the user activity data for a predetermined time; when it is analyzed that at least one pattern is included in the user activity data, determine a time point at which the user activity data including the at least one pattern is acquired, as a start time point of a user's food intake activity; store the user activity data as food intake data; and generate at least one piece of food intake information of the user on the basis of the food intake data.

The application discloses application of cloud weiling volatile oil in preparation of digestion-aiding and appetite-stimulating drugs. A preparation method of the cloud weiling volatile oil is as follows: cloud weiling medicinal materials are crushed, 8-10 times of water is added, and the mixture is refluxed at 90-100 DEG C for 3-5 hours, then the cloud weiling volatile oil is collected by a volatile oil extractor, dehydrated by adding anhydrous sodium sulfate, centrifuged, filtered, and obtained. The application provides application of the cloud weiling volatile oil in preparation of digestion-aiding and appetite-stimulating drugs. Experiments prove that the cloud weiling volatile oil can promote intestinal peristalsis, promote secretion of GAS and MTL, enhance pepsin activity and secretion, and increase food intake, and has the prospect of becoming a digestion-aiding and appetite-stimulating drug.

The invention discloses a curcumin nanocrystal aloe gel powder composition and application thereof, and belongs to the technical field of food, health care products and medicines. The curcumin nanocrystal aloe gel powder composition is characterized in that no surfactant is added; the curcumin nanocrystal is prepared only by using the aloe gel powder as a stabilizer to improve the dissolution rate of the curcumin, and the mass ratio of the curcumin to the aloe gel powder is (1: 1)-(1: 200). The preparation method comprises the following steps: preparing a curcumin nanocrystal aloe gel suspension by adopting a wet grinding or high-pressure homogenization method, and then drying by adopting a freeze-drying or spray-drying process. The curcumin nanocrystalline aloe gel powder disclosed by the invention has the effects of reducing blood sugar and blood fat, improving drinking water, ingestion and body weight, regulating intestinal flora and increasing abundance of hypoglycemic bacteria on diabetic mice, so that main visceral organs are protected, and the effects of improving diabetes and complications thereof are achieved.